BioSpace News Archive

MOBILion Systems, Inc. is partnering with Drs. Lance Wells and Michael Tiemeyer, principal investigators at the Complex Carbohydrate Research Center, University of Georgia, for evaluation of its patented ion mobility separations technology, called Structures for Lossless Ion Manipulation, for the research of glycans and glycoproteins.

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has added Gabrielle Sulzberger to serve as an independent member of its Board of Directors

Global Industry Leaders Join Inkbit to Enable High-Volume Production of Precision Multi-Material Parts

Bigfinite, Inc., the leading manufacturing data analytics platform company for regulated industries, announced that it has closed $15 million in financing with Atlantic Bridge, Honeywell Ventures and Institut Català de Finances.

Ironshore Pharmaceuticals Inc. (“Ironshore”), today announced that it will present data from a pivotal trial of JORNAY PM™ (methylphenidate HCl) extended-release capsules CII for the treatment of ADHD in patients 6 years and older and participate as a premier sponsor of the 31st Annual International Conference on ADHD in Philadelphia, November 6-9, 2019.

SpendEdge, a global procurement market intelligence firm, has announced the release of its Global Drug Substance Manufacturing Market - Procurement Intelligence Report.

In recognition of National Diabetes Month, Covetrus®, a global leader in animal-health technology and services, will donate $1 to The Pet Fund® for every order that includes a featured diabetes care product throughout November.

First-to-market functionality allows health plans and ACOs to automatically share actionable information about populations succinctly and in real-time with care teams across the Collective network

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 10:20 a.m. Mountain Time.

Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, announced positive interim efficacy data from the Company’s ongoing Phase Ib clinical trial in patients with severe sepsis.